☆ 4.2 Article

Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma

EXPERIMENTAL HEMATOLOGY (2017)

Journal

EXPERIMENTAL HEMATOLOGY

Volume 46, Issue -, Pages 48-55

Publisher

ELSEVIER SCIENCE INC

DOI: 10.1016/j.exphem.2016.11.004

Keywords

Funding

grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health Welfare [HI14C1898]
grant of the National Research Foundation of Korea (NRF) - Ministry of Education, Science, and Technology (MEST), Republic of Korea [2015R1D1A1A09057809]
National Research Foundation of Korea [2015R1D1A1A09057809] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

Lenalidomide (LEN) has been used as an immunomodulatory drug with direct and indirect anti-tumor effects. In this study, we evaluated the effect of LEN on the differentiation, maturation, and function of dendritic cells (DCs) in patients with multiple myeloma in vitro. Various doses of LEN were added after the monocytes had differentiated into immature DCs and were activated into mature DCs. LEN (5 mu g/mL) was the optimal concentration to promote differentiation and maturation of DCs. Immature DCs treated with LEN exhibited enhanced endocytic capacity. Mature DCs treated with LEN produced higher levels of interleukin-12p70, possessed stronger allogeneic T-cell stimulation capacity, reduced the number of suppressor cells, and generated antigen-specific cytotoxic T lymphocytes more potently compared with control DCs. These results suggest that LEN enhanced the function of DCs generated from patients with multiple myeloma by stimulating the capacity of allogeneic T cells, inhibiting the generation of immunosuppressive cells, inducing naive T cells toward Th1 polarization, and generating potent myeloma-specific cytotoxic T lymphocytes. Copyright (C) 2016 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2

Not enough ratings

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Pomalidomide enhances the maturation of dendritic cells derived from healthy donors and multiple myeloma patients

Xi Wang, Jingying Dai, Jingyi Xia, Zichen Ye, Xiaobing Huang, Wanjun Cao, Rong Xiao, Lin He

Summary: The study aims to investigate the effect of pomalidomide on the maturation of monocyte-derived dendritic cells (moDCs) from healthy donors (HDs) and multiple myeloma (MM) patients. The results show that pomalidomide enhances the maturation of moDCs and increases the expression of CD40 and HLA-DR on cells. However, the impact of pomalidomide on cytokine secretion levels varies between different sources of moDCs.

FRONTIERS IN PHARMACOLOGY (2022)